

ii) introducing said recombinant expression vector encoding said light chain and said recombinant expression vector encoding said heavy chain into a Chinese hamster ovary (CHO) cell.

iii) culturing said CHO cell resulting from step (ii) so that said light and heavy chains are produced and said antibody is thereby produced,

iv) recovering said antibody resulting from step (iii) and,

v) administering said antibody to said human in an amount sufficient to effect said treatment.

B' ent 28. The method according to claim 27 wherein said antibody is a human, chimeric, CDR grafted or bi-specific antibody.

29. The method according to claim 27 wherein said disorder is a T cell-mediated disorder.

30. The method according to claim 29, wherein the T-cell mediated disorder is an autoimmune disease.

31. The method according to claim 30, wherein the autoimmune disease is multiple sclerosis, graft vs. host

disease, psoriasis, juvenile onset diabetes, Sjogrens' disease, thyroid disease, myasthenia gravis, transplant rejection or asthma.

32. The method according to claim 29, wherein the T-cell mediated disorder is severe vasculitis, rheumatoid arthritis or systemic lupus.

33. The method according to claim 32, wherein the T-cell mediated disorder is rheumatoid arthritis.

34. The method according to claim 29, wherein the antibody is an anti-CDw52 antibody.

35. A method according to claim 29, wherein the antibody is an anti-CD4 antibody.

36. The method according to claim 27 wherein said disease is cancer.

37. The method according to claim 36, wherein the cancer is non-Hodgkins lymphoma.

38. The method according to claim 36, wherein the cancer is multiple myeloma.

39. A method according to claim 38, wherein the antibody specifically recognizes a T cell marker.

40. A method according to claim 39, wherein the antibody is an anti-CDw52 antibody.

41. A method according to claim 36, wherein the antibody specifically recognizes a cancer cell marker antigen.

42. A method according to claim 41, wherein the antibody is an anti-CD33 antibody or an anti-CD38 antibody.

43. The method according to claim 27 wherein said antibody is a CDR grafted antibody.

44. The method according to claim 27 wherein said antibody is a chimeric antibody.

45. The method according to claim 27 wherein said antibody specifically binds CD4.